27423-79-6

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
2-(3-FLUORO-PHENYL)-1H-IMIDAZOLE is used as a research compound for its potential pharmacological properties, including anti-inflammatory and antifungal effects. It is utilized in the development of new drugs targeting various medical conditions.
Used in Antifungal Treatments:
In the medical industry, 2-(3-FLUORO-PHENYL)-1H-IMIDAZOLE is used as an antifungal agent for treating fungal infections due to its ability to combat fungal pathogens.
Used in Inflammatory Disease Treatments:
2-(3-FLUORO-PHENYL)-1H-IMIDAZOLE is used as an anti-inflammatory agent for managing inflammatory diseases, leveraging its capacity to reduce inflammation and alleviate symptoms.
Used in Neurological Function Modulation:
In the field of neurology, 2-(3-FLUORO-PHENYL)-1H-IMIDAZOLE is used as a modulator of neurological function, with ongoing research exploring its potential to treat neurological disorders.
These applications highlight the versatility of 2-(3-Fluoro-phenyl)-1H-imidazole in different areas of medicine and underscore the importance of continued research to fully understand and harness its therapeutic potential.

InChI:InChI=1/C9H7FN2/c10-8-3-1-2-7(6-8)9-11-4-5-12-9/h1-6H,(H,11,12)

Upstream product

• 131543-46-9 Glyoxal 
• 456-48-4 3-Fluorobenzaldehyde 
• 403-54-3 m-Fluorobenzonitrile 
• 22483-09-6 2,2-dimethoxyethylamine 

Downstream Products

• 1217902-37-8 1-benzyl-2-(3-fluorophenyl)-1H-imidazole 

Relevant academic research and scientific papers

MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES

Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D2 mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).

Benzimidazole and pyridylimidazole derivatives

This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.

Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands

This invention relates to heteroaryl substituted fused bicyclic heteroaryl compounds, such as heteroaryl substituted imidazopyridines, imidazopyrazines, imidazopyridizines, imidazopyrimidines, and imidazothiazoles, which may be described by Formula I or F